Genmab A/S (NASDAQ:GMAB) Sets New 1-Year High – What’s Next?

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) reached a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $51.86 and last traded at $51.9180, with a volume of 3,001,698 shares. The stock had previously closed at $44.67.

Genmab A/S News Summary

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported that its Phase 3 LiGeR-HN1 trial of experimental drug petosemtamab combined with Merck’s Keytruda (pembrolizumab) achieved both primary endpoints in first-line, PD-L1-positive recurrent or metastatic head and neck cancer. The combination reduced the risk of death by 50% versus Keytruda alone and also improved objective response rates, regardless of patients’ HPV status. Genmab plans to consult regulators and submit the complete results for presentation at a future medical meeting. Genmab Phase 3 LiGeR-HN1 announcement
• Positive Sentiment: The strong survival data drove reports of a sharp rally and a new record high, with analysts describing the results as potentially supporting a new treatment standard for head and neck cancer. Genmab record high after cancer data
• Positive Sentiment: Analyst sentiment strengthened: Truist reaffirmed a Buy rating and raised its price target to $67 from $45, while HC Wainwright raised its target to $70 from $50 and initiated or maintained a Buy rating. Additional reports cited upgrades and bullish expectations from JPMorgan and TD Cowen.
• Positive Sentiment: Heavy call-option activity suggests speculative investors are positioning for further upside following the trial announcement. Genmab call-option activity
• Neutral Sentiment: Commentary remains divided on valuation. While some analysts argue GMAB could still be undervalued given petosemtamab’s potential commercial opportunity, others recommend waiting after the rapid appreciation and before full trial data and regulatory steps are available. Genmab valuation analysis

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. TD Cowen increased their target price on Genmab A/S from $43.00 to $52.00 and gave the company a “buy” rating in a research note on Monday. Guggenheim upped their price target on shares of Genmab A/S from $45.00 to $54.00 and gave the company a “buy” rating in a report on Monday, October 5th. HC Wainwright upped their price target on shares of Genmab A/S from $50.00 to $70.00 and gave the company a “buy” rating in a report on Thursday. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research note on Wednesday, July 22nd. Finally, JPMorgan Chase & Co. raised shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $49.06.

Genmab A/S Stock Down 1.4%

The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The firm has a market capitalization of $35.25 billion, a P/E ratio of 41.22, a P/E/G ratio of 2.47 and a beta of 0.81. The stock has a fifty day moving average price of $36.64 and a two-hundred day moving average price of $30.47.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.17. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. Research analysts forecast that Genmab A/S Sponsored ADR will post 1.22 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC grew its position in shares of Genmab A/S by 26.4% during the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after acquiring an additional 921,700 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Genmab A/S by 84.3% in the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after acquiring an additional 1,126,069 shares during the period. Quantinno Capital Management LP increased its holdings in shares of Genmab A/S by 14.4% in the 1st quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock worth $7,579,000 after acquiring an additional 35,588 shares during the period. Royal Bank of Canada increased its holdings in shares of Genmab A/S by 1.8% in the 1st quarter. Royal Bank of Canada now owns 150,135 shares of the company’s stock worth $4,029,000 after acquiring an additional 2,637 shares during the period. Finally, Legacy Wealth Asset Management LLC lifted its position in Genmab A/S by 164.1% in the 2nd quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock valued at $2,806,000 after purchasing an additional 63,484 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.